Triple Akt Inhibition as a New Therapeutic Strategy in T-cell Acute Lymphoblastic Leukemia

Thumbnail
View/ Open

Show full item record

Author
McCubrey, James A.
URI
http://hdl.handle.net/10342/9587
Subject
 T-acute lymphoblastic leukemia; Perifosine; small molecules inhibitors (SMI) 
Date
2015-03-02
Citation:
APA:
McCubrey, James A.. (March 2015). Triple Akt Inhibition as a New Therapeutic Strategy in T-cell Acute Lymphoblastic Leukemia. Oncotarget, (6:9), p.6597-6610. Retrieved from http://hdl.handle.net/10342/9587

Display/Hide MLA, Chicago and APA citation formats.

MLA:
McCubrey, James A.. "Triple Akt Inhibition as a New Therapeutic Strategy in T-cell Acute Lymphoblastic Leukemia". Oncotarget. 6:9. (6597-6610.), March 2015. May 23, 2022. http://hdl.handle.net/10342/9587.
Chicago:
McCubrey, James A., "Triple Akt Inhibition as a New Therapeutic Strategy in T-cell Acute Lymphoblastic Leukemia," Oncotarget 6, no. 9 (March 2015), http://hdl.handle.net/10342/9587 (accessed May 23, 2022).
AMA:
McCubrey, James A.. Triple Akt Inhibition as a New Therapeutic Strategy in T-cell Acute Lymphoblastic Leukemia. Oncotarget. March 2015; 6(9) 6597-6610. http://hdl.handle.net/10342/9587. Accessed May 23, 2022.
Collections